NASDAQ$PBYI
Puma Biotechnology Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Puma Biotechnology's financial performance was impacted by COVID-19 challenges, resulting in a net loss, while the company focused on supporting breast cancer patients and advancing clinical milestones.
Puma Biotechnology reported a net loss of $31.5 million for Q3 2020, impacted by COVID-19 challenges. Total revenue was $50.8 million, with NERLYNX revenue at $49.3 million. The company continued to advance clinical milestones and support breast cancer patients.
- Net NERLYNX revenue was $49.3 million, compared to $53.5 million in Q3 2019.
- Puma reported a net loss of $31.5 million, or $0.79 per share, compared to a net loss of $16.9 million, or $0.44 per share, for the third quarter of 2019.
- Non-GAAP adjusted net loss was $23.9 million, or $0.60 per share.
- Net cash provided by operating activities was $1.7 million.
Headline financials
Revenue & EPS history
Puma Biotechnology · Revenue · Quarterly
$50.8M
Revenue by segment
Puma Biotechnology · $1.5M total across 1 segment · Q3 2020
- Royalty Revenue$1.5M+1400.0%100.0%
Forward guidance
Puma Biotechnology anticipates several key milestones over the next 12 months, including reporting Phase II data from various SUMMIT trials, conducting a pre-NDA meeting with the FDA, and receiving regulatory decisions for an extended adjuvant HER2-positive early stage breast cancer indication in additional countries.
Tailwinds
- Reporting Phase II data from the SUMMIT trial of neratinib in hormone receptor positive breast cancer patients with HER2 mutations in the fourth quarter of 2020.
- Reporting additional data from the Phase II CONTROL trial in the fourth quarter of 2020.
- Reporting Phase II data from the SUMMIT trial of neratinib in bile duct cancer patients with HER2 mutations in the first quarter of 2021.
- Reporting Phase II data from the SUMMIT trial of neratinib in non-small cell lung cancer patients with EGFR exon 18 mutations in the first half of 2021.
- Conducting a pre-NDA meeting with the FDA to discuss accelerated approval of neratinib in HER2 mutated hormone receptor positive breast cancer and HER2 mutated cervical cancer in the first half of 2021.
Headwinds
- COVID-19 may continue to impact revenues going forward.
- Total other expenses were $19.4 million for the third quarter of 2020, largely attributable to a legal verdict expense of $15.9 million.
- Increased estimate of the legal accrual to $24.8 million.
- Uncertainties related to clinical trial outcomes.
- Risks associated with regulatory approvals.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
-1.6%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+4.4%
Avg return
30 days after
47%
21 / 45 earnings
Positive
+36.4%
Q4 2018
Best reaction
-45.8%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.8% | -6.0% | -5.8% | |
| Q4 2025 | -25.1% | -15.8% | -20.0% | |
| Q3 2025 | +21.8% | +1.8% | +8.2% | |
| Q1 2025 | -4.6% | -5.5% | +21.2% | |
| Q4 2024 | +19.7% | +18.4% | +5.0% | |
| Q3 2024 | -5.9% | +4.9% | +2.0% | |
| Q2 2024 | +6.7% | +12.3% | -30.4% | |
| Q1 2024 | -1.8% | -4.0% | -22.2% | |
| Q4 2023 | -10.8% | -21.5% | -19.7% | |
| Q3 2023 | +4.9% | +9.4% | +41.5% | |
| Q2 2023 | +5.8% | +13.3% | +2.5% | |
| Q1 2023 | +19.8% | +19.4% | +35.0% | |
| Q4 2022 | -20.1% | -26.6% | -23.1% | |
| Q3 2022 | +25.5% | +50.9% | +106.0% | |
| Q2 2022 | +23.5% | +17.4% | -17.0% | |
| Q1 2022 | -19.1% | -26.0% | -4.9% | |
| Q4 2021 | +13.5% | +25.7% | +34.2% | |
| Q3 2021 | -39.1% | -42.2% | -54.6% | |
| Q2 2021 | +3.6% | +3.6% | +7.9% | |
| Q1 2021 | +1.6% | -0.8% | +17.0% | |
| Q4 2020 | -11.9% | -11.9% | -12.6% | |
| Q3 2020 | -11.0% | +1.3% | +31.8% | |
| Q2 2020 | -5.7% | -7.9% | -11.6% | |
| Q1 2020 | +11.2% | +23.1% | +6.4% | |
| Q4 2019 | -2.4% | -18.8% | -43.9% | |
| Q3 2019 | +4.2% | +18.0% | +9.1% | |
| Q2 2019 | +26.7% | +25.8% | +22.1% | |
| Q1 2019 | -38.6% | -41.5% | -53.9% | |
| Q4 2018 | +36.4% | +35.3% | +35.9% | |
| Q3 2018 | -45.8% | -39.5% | -37.3% | |
| Q2 2018 | -7.5% | -7.1% | -2.1% | |
| Q1 2018 | -19.0% | -18.9% | -24.3% | |
| Q4 2017 | +8.7% | +16.7% | +4.1% | |
| Q3 2017 | -22.2% | -24.3% | -23.9% | |
| Q2 2017 | -11.6% | -1.7% | +28.0% | |
| Q1 2017 | +1.5% | +4.3% | +163.9% | |
| Q4 2016 | -10.6% | -8.3% | +1.4% | |
| Q3 2016 | +21.3% | -0.5% | -9.4% | |
| Q3 2015 | -9.6% | — | — | |
| Q1 2015 | +2.0% | — | — | |
| Q4 2014 | -3.3% | — | — | |
| Q1 2013 | +3.7% | — | — | |
| Q3 2012 | -6.4% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +1.9% | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro